NYSE · VTR
Real Estate · REIT - Healthcare Facilities
$90.27
Down-$1.84 (-2.00%)
Updated Sep 6, 2026, 4:46 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VTR closed at $90.27 after 20 trading sessions, down 1.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $91.32 | $92.22 | $90.15 | $90.27 | 3.5M |
| Sep 3, 2026 | $92.47 | $92.99 | $91.59 | $92.11 | 2.8M |
| Sep 2, 2026 | $91.97 | $92.76 | $90.915 | $92.06 | 2.79M |
| Sep 1, 2026 | $92.01 | $93.37 | $91.41 | $92.07 | 3.35M |
| Aug 31, 2026 | $91.17 | $91.60 | $90.285 | $91.17 | 4.25M |
| Aug 28, 2026 | $93.42 | $93.83 | $91.73 | $91.81 | 1.92M |
| Aug 27, 2026 | $92.36 | $93.18 | $91.59 | $92.89 | 1.53M |
| Aug 26, 2026 | $93.94 | $94.50 | $93.22 | $93.50 | 2.18M |
| Aug 25, 2026 | $93.57 | $94.40 | $92.8301 | $93.83 | 2.92M |
| Aug 24, 2026 | $93.45 | $94.4475 | $92.625 | $93.47 | 2.13M |
| Aug 21, 2026 | $92.61 | $94.31 | $92.00 | $93.06 | 2.75M |
| Aug 20, 2026 | $91.93 | $93.68 | $91.75 | $92.68 | 2.09M |
| Aug 19, 2026 | $91.63 | $92.02 | $91.01 | $91.85 | 5.61M |
| Aug 18, 2026 | $90.28 | $92.35 | $90.28 | $91.20 | 3.08M |
| Aug 17, 2026 | $91.29 | $91.63 | $90.405 | $91.17 | 2.91M |
| Aug 14, 2026 | $90.19 | $91.615 | $90.155 | $91.52 | 3M |
| Aug 13, 2026 | $89.49 | $90.57 | $89.35 | $90.29 | 2.31M |
| Aug 12, 2026 | $86.94 | $89.14 | $86.94 | $89.01 | 2.56M |
| Aug 11, 2026 | $90.82 | $90.89 | $86.92 | $86.96 | 4.89M |
| Aug 10, 2026 | $92.00 | $92.97 | $91.54 | $91.95 | 2.89M |
The latest Smart Investors Daily articles mentioning VTR.
VTR research
Company profile and research snapshot.
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Scotiabank | Sector Perform | — |
| Sep 1, 2026 | Wells Fargo | Overweight | — |
| Aug 31, 2026 | Barclays | Equal-Weight | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 11, 2026 | BMO Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Benzinga · Sep 2, 2026
Scotiabank analyst Nicholas Yulico maintains Ventas (NYSE:VTR) with a Sector Perform and raises the price target from $93 to $95.
Benzinga · Sep 1, 2026
Wells Fargo analyst John Kilichowski maintains Ventas (NYSE:VTR) with a Overweight and raises the price target from $96 to $104.
Benzinga · Aug 31, 2026
Barclays analyst Richard Hightower maintains Ventas (NYSE:VTR) with a Equal-Weight and raises the price target from $99 to $102.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTR.
